Galectin Therapeutics
GALT
NASDAQ
IPO2002
about GALT
Galectin Therapeutics develops therapeutic treatments targeting galectins, with its lead product Galafold approved for treating Fabry disease by addressing enzyme deficiencies to improve kidney function.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $4.64 | $4.83 | $3.80 | $397.15M | 4.12M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.13 | n/a | n/a | 0% | 0% | 0% |